Surrozen Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SRZN Nasdaq 8731 https://www.surrozen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Surrozen Inc

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke - Jun 5th, 2023 12:30 pm
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates - May 10th, 2023 8:05 pm
Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt - Apr 5th, 2023 12:30 pm
Surrozen, Inc. (NASDAQ:SRZN) Q4 2022 Earnings Call Transcript - Mar 28th, 2023 8:59 am
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress - Mar 22nd, 2023 8:01 pm
Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023 - Mar 20th, 2023 8:30 pm
Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 4th, 2023 9:41 pm
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 14th, 2022 9:30 pm
Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week - Oct 10th, 2022 12:00 pm
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases - Oct 6th, 2022 12:00 pm
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy - Sep 26th, 2022 12:00 pm
Surrozen Reports Second Quarter 2022 Financial Results - Aug 11th, 2022 12:00 pm
What Is The Ownership Structure Like For Surrozen, Inc. (NASDAQ:SRZN)? - Jun 27th, 2022 2:34 pm
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis - Jun 13th, 2022 12:00 pm